Qatar Investment Authority, a private equity firm founded by the State of Qatar, agreed to lead an investment in BridgeBio Pharma, a commercial-stage biopharmaceutical company, with participation from TD Cowen, Mizuho, and KKR Capital Markets. Financial terms were not disclosed. “We are very pleased to partner with such a strong group of investors. Their support will help us fund our future operations, including the launch of acoramidis and our upcoming Phase 3 readouts in achondroplasia, LGMD2I, and ADH1, and will allow us to pursue additional less dilutive financing options to optimize our cost of capital,” Neil Kumar, BridgeBio Founder and CEO.